We have shown that cysteine is a facilitator for cancer cells’ adaption to hypoxia and also to carboplatin, and for most ovarian cancer cell lines this adaptive capacity relies on CD133+ cells, putatively cancer stem cells [115,116]. This evidence concerns the gene PROM1 and cancer.